Anzeige
Mehr »
Login
Mittwoch, 22.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Mit dieser Aktie könntest Du von der Cannabis-Legalisierungswelle profitieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C9EJ | ISIN: US45258H1068 | Ticker-Symbol:
NASDAQ
22.05.24
21:51 Uhr
2,190 US-Dollar
-0,070
-3,10 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
IMMIX BIOPHARMA INC Chart 1 Jahr
5-Tage-Chart
IMMIX BIOPHARMA INC 5-Tage-Chart

Aktuelle News zur IMMIX BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoImmix Biopharma, Inc. - 8-K, Current Report1
MoImmix Biopharma - All roads lead to NEXICART-2143Immix Biopharma's Q124 report reflected a period focused on its lead CAR-T asset, NXC-201, targeting amyloid light chain amyloidosis (ALA), which was recently bolstered by incremental NEXICART-1 data....
► Artikel lesen
10.05.Immix Biopharma, Inc.: Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation6592% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to NXC-201...
► Artikel lesen
09.05.Immix Biopharma, Inc. - 10-Q, Quarterly Report1
29.04.Immix Biopharma, Inc.: Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma404European Orphan Drug Designation ("ODD") qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for: EU protocol...
► Artikel lesen
18.04.Immix Biopharma, Inc.: Immix Biopharma on Track to Dose NXC-201 Patients in United States384Scheduling U.S. site initiation visits April and May 2024On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S. sites mid-2024...
► Artikel lesen
15.04.Immix Biopharma, Inc.: Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)87Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory AL amyloidosis will be presented in Baltimore May 7-11, 2024 LOS ANGELES, April 15, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma...
► Artikel lesen
03.04.Immix Biopharma - Reaffirmed long-term focus on outpatient CAR-T242Immix Biopharma is continuing its strategic pivot towards exploring non-traditional indications for its CAR-T asset, NXC-201, leading with relapsed/refractory (r/r) amyloid light chain amyloidosis (ALA)....
► Artikel lesen
02.04.Immix Biopharma Inc reports results for the quarter ended in December - Earnings Summary1
29.03.Immix Biopharma, Inc. - 10-K, Annual Report1
26.03.Immix Biopharma - Marching towards US clinical trials for NXC-201257Immix Biopharma is closer to dosing its first US patient for lead CAR-T asset NXC-201, with the appointment of the Memorial Sloan Kettering Cancer Center as the main clinical site for the company's...
► Artikel lesen
25.03.Immix Biopharma Inc expected to post a loss of 23 cents a share - Earnings Preview1
20.03.Immix Biopharma, Inc.: Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial1
05.03.Immix Biopharma, Inc.: Immix Biopharma Announces "Be Proactive in AL" AL Amyloidosis Awareness Initiative1
27.02.Immix Biopharma - 2023 recap with a preview of active year ahead265Immix has shared a 12-month recap, capturing key clinical and regulatory events from 2023, setting the stage for an active 2024. Its lead CAR-T asset (NXC-201) is a B-cell maturation antigen (BCMA)...
► Artikel lesen
21.02.Immix Biopharma, Inc.: Immix Biopharma 12 Month Review Progress Update831LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its...
► Artikel lesen
12.02.Immix Biopharma - Updates galore: NXC-201 ODD (EU) and raise262Immix Biopharma has released back-to-back updates, including EU orphan drug designation (ODD) for its lead CAR-T asset NXC-201, addressing amyloid light chain amyloidosis (ALA), and pricing of its $15m...
► Artikel lesen
08.02.Immix Biopharma, Inc.: Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock-
07.02.Immix Biopharma, Inc.: Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis465European Orphan Drug Designation ("ODD") qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for EU protocol...
► Artikel lesen
07.02.Immix Biopharma - Increased legroom following common-only raise248Immix Biopharma has announced a $15m (gross), fully underwritten equity issue. The company will use the proceeds to fund clinical trials for lead CAR-T asset NXC-201, as well as to meet working capital...
► Artikel lesen
Seite:  Weiter >>
49 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1